ATE238794T1 - Verwendung von einem draflazin analog zur schmerzbehandlung - Google Patents

Verwendung von einem draflazin analog zur schmerzbehandlung

Info

Publication number
ATE238794T1
ATE238794T1 AT98934969T AT98934969T ATE238794T1 AT E238794 T1 ATE238794 T1 AT E238794T1 AT 98934969 T AT98934969 T AT 98934969T AT 98934969 T AT98934969 T AT 98934969T AT E238794 T1 ATE238794 T1 AT E238794T1
Authority
AT
Austria
Prior art keywords
phenyl
draflazine
analog
derivative
4alkyl
Prior art date
Application number
AT98934969T
Other languages
English (en)
Inventor
Theo Frans Meert
Belle Herman Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE238794T1 publication Critical patent/ATE238794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98934969T 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung ATE238794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201813 1997-06-16
PCT/EP1998/003664 WO1998057643A1 (en) 1997-06-16 1998-06-09 Use of draflazine-analogues for treating pain

Publications (1)

Publication Number Publication Date
ATE238794T1 true ATE238794T1 (de) 2003-05-15

Family

ID=8228446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934969T ATE238794T1 (de) 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung

Country Status (10)

Country Link
US (1) US6403589B1 (de)
EP (1) EP0999840B1 (de)
JP (1) JP2002504134A (de)
KR (1) KR20010013387A (de)
AT (1) ATE238794T1 (de)
AU (1) AU8438798A (de)
CA (1) CA2294011A1 (de)
DE (1) DE69814089T2 (de)
ES (1) ES2199447T3 (de)
WO (1) WO1998057643A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006137A (es) * 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
EA012367B1 (ru) 2002-09-05 2009-10-30 Ньюроджескс, Инк. Композиция и способ очистки поверхности тела от капсаицина, набор и способ лечения боли
JPWO2004101593A1 (ja) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 5’−修飾ヌクレオシド誘導体及びその医薬用途
CA2602796A1 (en) * 2005-04-01 2006-10-12 Neurogesx, Inc. Oils of capsaicinoids and methods of making and using the same
TW201113280A (en) 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cns及び関連障害の治療において使用するためのインドリン−2−オン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368280A1 (fr) 1976-10-20 1978-05-19 Theramex Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
FR2513118A1 (fr) 1981-09-18 1983-03-25 Rocador Sa Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire
NZ223847A (en) * 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
US5236908A (en) 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs

Also Published As

Publication number Publication date
EP0999840B1 (de) 2003-05-02
DE69814089T2 (de) 2004-02-19
JP2002504134A (ja) 2002-02-05
EP0999840A1 (de) 2000-05-17
DE69814089D1 (de) 2003-06-05
US6403589B1 (en) 2002-06-11
CA2294011A1 (en) 1998-12-23
ES2199447T3 (es) 2004-02-16
KR20010013387A (ko) 2001-02-26
AU8438798A (en) 1999-01-04
WO1998057643A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
MY128664A (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
CY1108813T1 (el) Αναστολεις κινασων τυροσινης
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR9809185A (pt) Diidropiranos fundidos
PT705100E (pt) Guanidinas substituidas terapeuticas
NO990662L (no) Trombin-inhibitorer
BG100016A (bg) Нiv протеазни инхибитори във фармацевтични комбинации за лечение на спин
IN2005KO00312A (de)
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
DE69814089D1 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
FI935779L (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
MXPA04005809A (es) Inhibidores de proteinas quinasas.
GB9907571D0 (en) Compounds
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties